Kloepfel MagazinKloepfel Magazin
    Top Article

    Kloepfel Group awarded “Best Consultants” for the eighth year in a row

    20. March 2023

    Technical procurement

    20. March 2023

    Technical sourcing: Win-win for customers and suppliers instead of price squeezers

    20. March 2023
    Facebook Twitter Instagram
    • Kloepfel Group
    • Kloepfel Consulting
    • Kloepfel Karriere
    LinkedIn Twitter Facebook Instagram YouTube
    Kloepfel MagazinKloepfel Magazin
    • START
    • NEWS
      • HWWI
      • INTERVIEWS
      • CAREER
      • KLOEPFEL GROUP
      • WHITEPAPER
      • SURVEY
      • INDUSTRY NEWS
        • ENGINEERING
        • LOGISTICS
        • SUPPLY CHAIN
    • NEWSLETTER
    • CONTACT
      • IMPRINT
      • PRIVACY POLICY
    Kloepfel MagazinKloepfel Magazin
    Home»Industry News»Supply Chain»Bayer presents its innovation strategy
    Supply Chain

    Bayer presents its innovation strategy

    By Kloepfel25. January 20212 Mins Read
    LinkedIn Facebook WhatsApp Email
    Das Bayer-Kreuz bei Nacht -------------------------- The Bayer Cross at night
    Share
    LinkedIn Facebook Twitter WhatsApp Email

    Progress in transformation of pharmaceuticals business

    Bayer reported progress in transforming its pharmaceuticals business at a conference last week.
    The virtual event, called Pharma Media Day, was themed “Transforming Healthcare. Transforming Bayer.” During the conference, the company explained how it is driving its strategy in cell and gene therapy, digital health and its development portfolio.

    Regarding its current transformation, the company wrote in the headline of its press release, “Bayer transforms pharma business with breakthrough innovations.” According to the company, the focus will be on innovations in healthcare for patients suffering from diseases that are currently difficult to treat.

    To achieve its goals, the Leverkusen-based company relies, among other things, on external innovations. Accordingly, Bayer informs that intensive investments have been made in such innovations in recent times. For example, more than 25 cooperation agreements and acquisitions were concluded in 2020.

    Platform for cell and gene therapy

    Stefan Oelrich, member of the Board of Management of Bayer AG and head of Bayer’s Pharmaceuticals Division, explained the realignment as follows: “The biomedical and technological revolution that is impacting healthcare at unprecedented speed is happening now. Our company is at the forefront of the wave of innovation in cell and gene therapy and in digital healthcare.”

    Bayer has built a new platform for cell and gene therapy. The company plans to use it to manage the strategy of this area. It will also be used to coordinate all activities within the value chain. According to the press release, this platform provides an innovation ecosystem for all of Bayer’s partners in this field.

    Digital health offerings

    Bayer says it expects digital health offerings to become an important pillar of modern healthcare. In this context, the Group sees advantages in combining conventional healthcare with innovative digital technologies.

    That is why the decision was made to make integrated healthcare a central element of the business strategy in the digital field. Here, Bayer is working with Informed Data Systems Inc. among others, a healthcare company specializing in digital solutions.

    Summing up developments in Bayer’s Pharmaceuticals Division, Stefan Oelrich said, “We are driving forward the transformation of our business and are expanding our promising development portfolio together with our partners. Our common goal is to provide patients with breakthrough therapies and make healthcare systems more sustainable in the medium and long term.”

    Quelle: www.kloepfel-consulting.com

    Share. LinkedIn Facebook Twitter WhatsApp Email

    Related Posts

    Stellantis invests $155 million in McEwen Copper

    20. March 2023

    Significantly fewer companies planning price increases

    20. March 2023

    BMW buys aluminum from sustainable production

    20. March 2023

    Stellantis buys nickel sulfate from Terrafame

    13. February 2023

    “Collaboration in the Supply Chain”

    13. February 2023

    Producer prices up 21.6 percent year-on-year in December

    13. February 2023

    Comments are closed.

    Top Artikel

    Kloepfel Group awarded “Best Consultants” for the eighth year in a row

    By Kloepfel20. March 2023

    As part of a representative survey conducted by the independent business magazine brand eins and…

    Technical procurement

    20. March 2023

    Technical sourcing: Win-win for customers and suppliers instead of price squeezers

    20. March 2023

    In procurement lies the profit

    20. March 2023

    Dangers from cyber attacks

    20. March 2023
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • LinkedIn
    About us
    About us

    Das Magazin für den effektiveren Einkauf!

    Kloepfel Consulting GmbH
    Pempelforter Strsse 50
    40211 Düsseldorf

    Telefon: +49 211 941 984 33
    E-Mail: info@kloepfel-consulting.com

    New Article

    Kloepfel Group awarded “Best Consultants” for the eighth year in a row

    20. March 2023

    Technical procurement

    20. March 2023

    Technical sourcing: Win-win for customers and suppliers instead of price squeezers

    20. March 2023
    © 2023 Kloepfel Consulting GmbH All rights reserved
    • Home
    • News
    • Contact
    • Imprint
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.